Investigational drug · Phase 2
PM1009
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HCC, Liver Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PM1009"
First trial start
2024
Dec 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PM1009", any sponsor or status.
Conditions studied
As listed on its trial records.
- HCC
- Liver Cancer
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "PM1009" as an intervention, largest first.
- A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCNot yet recruiting
Biotheus Inc.Industry
NCT06584071 · 140 participants (planned) · Start Dec 2024 · Primary completion Oct 2026
Drug: PM8002; PM1009 and 2 more · For: HCC; Liver Cancer
Biotheus Inc.Industry
NCT05607563 · 54 participants (planned) · Start Nov 21, 2022 · Primary completion Nov 2023
Drug: PM1009 injection · For: Advanced Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HCC
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- tirapazaminePhase 32 trials
Zhejiang Raygene Pharmaceuticals Co., Ltd · HCC, Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- GNOS-PV02Phase 22 trials
Geneos Therapeutics · HCC
- FOG-001Phase 21 trial
Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.